#read

WACKER and Gearbox Biosciences are working together to further develop technologies for the production of plasmid DNA

WACKER and Gearbox Biosciences are joining forces to rethink the production of plasmid DNA. The aim is to develop processes that do not require antibiotics, work more efficiently and can reliably produce even complex sequences.

06/08/2025

Plasmid DNA is a key building block for modern mRNA vaccines, gene therapies and other high-tech drugs. The partnership combines WACKER's expertise in GMP manufacturing with Gearbox's pop-out plasmid technology. The companies aim to set new standards in scalability, quality and sustainability. Initial tests are already underway at the WACKER Biotechnology Centre in Munich and on the production lines in San Diego. If the transfer from laboratory to industrial scale is successful, this could not only reduce manufacturing costs, but also remove regulatory hurdles and accelerate global access to innovative therapies.

Press release "Leipzig University Hospital" dated 31/07/2025

The above texts, or parts thereof, were automatically translated from the original language text using a translation system (DeepL API).
Despite careful machine processing, translation errors cannot be ruled out.

Click here to access the original content